Hematology
Conference Coverage
Rivaroxaban bonus: Early unmasking of occult GI cancers
MUNICH – Secondary analysis of COMPASS trial hits pay dirt.
From the Journals
Hormonal contraceptive use linked to leukemia risk in offspring
Maternal use of hormonal contraceptives close to pregnancy is associated with a small increase in the risk of nonlymphoid leukemia in offspring....
Latest News
Caplacizumab approved in Europe to treat aTTP
The drug is under priority review by the U.S. Food and Drug Administration.
Latest News
Emicizumab beats factor VIII prophylaxis by a wide margin
In the HAVEN 3 trial, patients with hemophilia A without inhibitors had a significant reduction in bleeding events and no thrombotic events.
From the Journals
Cervical cancer screening recommendations vary by age and risk
Conference Coverage
Integrated pain program reduced LOS for sickle cell patients
WASHINGTON – The small study is another data point showing the importance of multidisciplinary care.
Conference Coverage
A new, simple, inexpensive DVT diagnostic aid
NEW ORLEANS – The CBC holds info that outperforms the D-dimer test.
From the Journals
Groups release guidelines for CAR T treatment in children
Some of the tools used to detect toxicity that are used in older patients don’t work well in children.
News
FDA warns against azithromycin in blood or lymph node cancers
Azithromycin can lead to relapse and death when used to prevent an inflammatory lung condition in patients with blood or lymph node cancers who...
Feature
In Ghana, SCD research is meeting patients on home turf
The West African nation stands ready to solve the geographic mismatch between research capacity and patient population.
News
FDA approves IDH1 inhibitor for relapsed/refractory AML
The oral medication is the first and only FDA-approved treatment for relapsed/refractory AML with an IDH1 mutation.